AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Prognostic Significance of ctDNA in HL

Recruitingn/aAges 18 Years - anyAllInterni hematologicka klinika FNKV
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and โ‰ฅ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients โ‰ฅ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled * signing the informed consent Exclusion Criteria: * Pacients without signing the informed consent
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

5 sites
University Hospital Hradec Kralove
Hradec Krรกlovรฉ, Czechia
University Hospital Olomouc
Olomouc, Czechia
University Hospital Kralovske Vinohrady
Prague, Czechia
Charles University
Prague, Czechia
General University Hospital
Prague, Czechia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy